Adnavance Technologies Inc.
This article was originally published in Start Up
Executive Summary
Even though mortality rates double each day an MRSA infection remains untreated, most hospitals have to outsource diagnostics test to off-site labs, losing precious treatment time. Adnavance Technologies hopes to change this. The company's ADNAstat amplification-free technology enalbes rapid detection of MRSA DNA on-site at any hospital.